{
  "id": 1679523,
  "title": "OpenAI’s former exec disagrees with Amodei on most things, but backs his AI cancer view",
  "url": "https://urgent.news/2026/08/18/openais-former-exec-disagrees-with-amodei-on-most-things-but-backs",
  "topic": "ai",
  "section": "AI",
  "published": "2026-08-18T08:22:00.000Z",
  "source": {
    "name": "Times of India",
    "slug": "times-of-india",
    "url": "https://timesofindia.indiatimes.com/technology/tech-news/openais-former-top-exec-fidji-simo-admits-that-she-disagrees-with-dario-amodei-on-most-things-but-says-he-is-spot-on-treatment-of-/articleshow/133316342.cms"
  },
  "original_language": "en",
  "account": null,
  "summary": "Fidji Simo concurs with Dario Amodei on the crucial need for AI companies to demonstrate genuine medical advancements. It's essential for these enterprises to show tangible outcomes rather than relying solely on marketing strategies. Simo identifies biological data as a critical hurdle in developing AI-based treatments, particularly noting that cancer research benefits from vast pre-existing…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}